Revance announces pricing of public offering of common stock
Revance Therapeutics announced pricing of an underwritten public offering of 5,338,709 shares of its common stock at a price to the public of $31.00 per share. Revance and the Selling Stockholders have granted underwriters a 30-day option to purchase up to an aggregate of additional 800,806 shares. December 07, 2017